Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
CytoVeris
AddedFeb 15, 2024
UpdatedJun 18, 2026
CytoVeris

CytoVeris

Series B

AI-driven imaging solutions by CytoVeris, enhancing cancer detection and patient outcomes.

HQ
Farmington, CT, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

CytoVeris was founded with the mission to enhance intraoperative cancer detection through AI-powered imaging solutions, aiming to improve surgical outcomes and accessibility for both surgeons and patients. The company focuses on developing advanced imaging technologies that assist surgeons in making more precise decisions during cancer resections, thereby preserving healthy tissue and reducing the need for additional surgeries. Their primary market includes healthcare providers and surgical centers specializing in oncology.

Notable figures associated with CytoVeris include experts in medical imaging and artificial intelligence, though specific names are not provided. The company has attracted attention from investors interested in healthcare innovation. Key achievements include the development of their flagship AI-driven imaging system, which has shown promise in improving the precision of cancer surgeries. CytoVeris' impact is significant in the medical field, offering a potential reduction in repeat surgeries and better overall patient outcomes.

CytoVeris - Similar Companies

Vergent Bioscience logo

Vergent Bioscience

vergentbio.com

Cision Vision logo

Cision Vision

cisionvision.com

Sanus Solutions logo

Sanus Solutions

sanussolutions.com

surgical.ai logo

surgical.ai

surgical.ai

Radiosight logo

Radiosight

radiosight.com

BioVeras logo

BioVeras

CytoSite Biopharma logo

CytoSite Biopharma

CytoAgents logo

CytoAgents

cytoagents.com

CairnSurgical logo

CairnSurgical

ChestAi logo

ChestAi

CytoViva logo

CytoViva

cytoviva.com

Vysioneer logo

Vysioneer

vysioneer.com

Cybrexa logo

Cybrexa

cybrexa.com

Verix Health logo

Verix Health

Techcyte logo

Techcyte

techcyte.com

CytoVeris - Quick Facts

Who are CytoVeris' competitors?

Companies similar to CytoVeris include Vergent Bioscience, Cision Vision, Sanus Solutions and surgical.ai.

When was CytoVeris founded?

CytoVeris was founded in 2018.

Where is CytoVeris' headquarters located?

CytoVeris' headquarters is located in Farmington, CT, US.

When was CytoVeris' last funding round?

CytoVeris' most recent funding round was for $4.3M (USD) in May 2020.

How much has CytoVeris raised to-date?

As of May 1, 2020, CytoVeris has raised a total of $8M (USD).

How many employees does CytoVeris have?

CytoVeris has 23 employees as of Feb 5, 2024.

CytoVeris - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Americas
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Imaging Solutions
Tags
  • AI Operations
  • Healthcare
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified